KhvorovaA and WattsJK. (2017). The chemical evolution of oligonucleotide therapies of clinical utility. Nat Biotechnol, 35:238–248.
2.
KarikoK, BucksteinM, NiH and WeissmanD. (2005). Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity, 23:165–175.
3.
KarikoK, MuramatsuH, WelshFA, LudwigJ, KatoH, AkiraS and WeissmanD. (2008). Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol Ther, 16:1833–1840.
4.
SvitkinYV, ChengYM, ChakrabortyT, PresnyakV, JohnM and SonenbergN. (2017). N1-methyl-pseudouridine in mRNA enhances translation through eIF2alpha-dependent and independent mechanisms by increasing ribosome density. Nucleic Acids Res, 45:6023–6036.
5.
AndriesO, Mc CaffertyS, De SmedtSC, WeissR, SandersNN and KitadaT. (2015). N(1)-methylpseudouridine-incorporated mRNA outperforms pseudouridine-incorporated mRNA by providing enhanced protein expression and reduced immunogenicity in mammalian cell lines and mice. J Control Release, 217:337–344.
6.
WeissmanD, NiH, ScalesD, DudeA, CapodiciJ, McGibneyK, AbdoolA, IsaacsSN, CannonG and KarikoK. (2000). HIV gag mRNA transfection of dendritic cells (DC) delivers encoded antigen to MHC class I and II molecules, causes DC maturation, and induces a potent human in vitro primary immune response. J Immunol, 165:4710–4717.
7.
KimKQ, BurguteBD, TzengSC, JingC, JungersC, ZhangJ, YanLL, VierstraRD, DjuranovicS, EvansBS and Zaher.HS (2022). N1-methylpseudouridine found within COVID-19 mRNA vaccines produces faithful protein products. Cell Rep, 40:111300.
8.
SvidritskiyE, MadireddyR and KorostelevAA. (2016). Structural basis for translation termination on a pseudouridylated stop codon. J Mol Biol, 428:2228–2236.
9.
PotapovV, FuX, DaiN, CorreaIRJr., TannerNA and OngJL. (2018). Base modifications affecting RNA polymerase and reverse transcriptase fidelity. Nucleic Acids Res, 46:5753–5763.
ZhangZ, OhtoU, ShibataT, KrayukhinaE, TaokaM, YamauchiY, TanjiH, IsobeT, UchiyamaS, MiyakeK and ShimizuT. (2016). Structural analysis reveals that toll-like receptor 7 is a dual receptor for guanosine and single-stranded RNA. Immunity, 45:737–748.
12.
GreulichW, WagnerM, GaidtMM, StaffordC, ChengY, LinderA, CarellT and Hornung.V (2019). TLR8 is a sensor of RNase T2 degradation products. Cell, 179:1264.e1213–1275.e1213.
13.
HeilF, HemmiH, HochreinH, AmpenbergerF, KirschningC, AkiraS, LipfordG, WagnerH and BauerS. (2004). Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science, 303:1526–1529.
14.
DieboldSS, KaishoT, HemmiH, AkiraS and Reis e SousaC. (2004). Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science, 303:1529–1531.
15.
OstendorfT, ZillingerT, AndrykaK, Schlee-GuimaraesTM, SchmitzS, MarxS, BayrakK, LinkeR, SalgertS, et al. (2020). Immune sensing of synthetic, bacterial, and protozoan RNA by toll-like receptor 8 requires coordinated processing by RNase T2 and RNase 2. Immunity, 52:591.e596–605.e596.
16.
KarikoK, MuramatsuH, LudwigJ and Weissman.D (2011). Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA. Nucleic Acids Res, 39:e142.
17.
KonarskaMM and SharpPA. (1989). Replication of RNA by the DNA-dependent RNA polymerase of phage T7. Cell, 57:423–431.
18.
MuX, GreenwaldE, AhmadS and HurS. (2018). An origin of the immunogenicity of in vitro transcribed RNA. Nucleic Acids Res, 46:5239–5249.
19.
PeisleyA, LinC, WuB, Orme-JohnsonM, LiuM, WalzT and HurS. (2011). Cooperative assembly and dynamic disassembly of MDA5 filaments for viral dsRNA recognition. Proc Natl Acad Sci U S A, 108:21010–21015.
20.
DonovanJ, WhitneyG, RathS and KorennykhA. (2015). Structural mechanism of sensing long dsRNA via a noncatalytic domain in human oligoadenylate synthetase 3. Proc Natl Acad Sci U S A, 112:3949–3954.
21.
NaylorR, HoNW and GilhamPT. (1965). Selective chemical modifications of uridine and pseudouridine in polynucleotides and their effect on the specificities of ribonuclease and phosphodiesterases. J Am Chem Soc, 87:4209–4210.
22.
AndersonBR, MuramatsuH, JhaBK, SilvermanRH, WeissmanD and KarikoK. (2011). Nucleoside modifications in RNA limit activation of 2'-5'-oligoadenylate synthetase and increase resistance to cleavage by RNase L. Nucleic Acids Res, 39:9329–9338.
23.
MaugerDM, CabralBJ, PresnyakV, SuSV, ReidDW, GoodmanB, LinkK, KhatwaniN, ReyndersJ, MooreMJ and McFadyenIJ. (2019). mRNA structure regulates protein expression through changes in functional half-life. Proc Natl Acad Sci U S A, 116:24075–24083.
24.
GoteV, BollaPK, KommineniN, ButreddyA, NukalaPK, PalakurthiSS and Khan.W (2023). A comprehensive review of mRNA vaccines. Int J Mol Sci, 24:2700.
25.
KuhnAN, DikenM, KreiterS, SelmiA, KowalskaJ, JemielityJ, DarzynkiewiczE, HuberC, TureciO and SahinU. (2010). Phosphorothioate cap analogs increase stability and translational efficiency of RNA vaccines in immature dendritic cells and induce superior immune responses in vivo. Gene Ther, 17:961–971.
